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N-type voltage-dep endent Ca2+channels (VDCCs), expressed predominant ly in the nervous system, play 
pivotal roles in sympat hetic regulation of the circulatory system. Although N-type VDCCs are also report- 
edly expressed in the vasculature, their pathophysiological role is obscure. We demonstrated that oxida- 
tive stress-rela ted endothelial dysfunction induced by angiotensin (Ang) II is suppressed in mice lacking 
the N-type VDCC a1B subunit (Cav 2.2). Impairment of endothelium-dependent relaxation of the thoracic 
aorta observed following Ang II treatment in wild-type (WT) mice was signiﬁcantly attenuate d in the Ang 
II-treated Cav 2.2-deﬁcient mice, despite the comparable increase of the blood pressure in the two groups 
of mic e. The thoracic aorta of the Cav 2.2-deﬁcient mice showed a smaller positive area of oxidative stress 
markers as compared to the WT mice. The Ang II-induced endothelial dysfunction was also suppressed by
cilnidipine, an L/N-type VDCC blocker, but not by amlodipine, an L-type VDCC blocker; however, this 
unique effect of cilnidipine was completely abolished in the Cav 2.2-deﬁcient mice. Furthermore, selec- 
tive inhibition of N-type VDCCs by x-conotoxin GVIA dramatically suppressed the production of reactive 
oxygen species (ROS) as well as agonist-induced Ca2+ inﬂux in the vascular endothelial cells. These results 
suggest that N-type VDCCs expressed in the vascular endothelial cells contribute to ROS production and 
endothelial dysfunction observed in Ang II-treated hypertensive mic e.
 2013 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction 
Vascular endothelium is a major modulato r of the vascular tone,
releasing vasoactive substances such as endothelium -derived 
relaxing factor (EDRF), endothelium -derived hyperpolarizing fac- n; AT1R, Ang type1 receptor;
ethidium; DHP, dihydropyri- 
EDHF, endothelium-derived 
 relaxing factor; 4-HNE, 4-
 weight; LTCCs, L-type Ca2+
xy-2 0-deoxyguanosine; ROS,
a2+ channels; WT, wild-type.
M. Nishida), tatsuya_ishika-
mamoto-u.ac.jp (S. Kim-Mit- 
Y-NC-ND license.tors (EDHFs), cycloxygenase metaboli tes, and endothelium -derived 
constrict ing factors (EDCFs) [1,2]. The balanced release of these 
factors is altered in several cardiovascular pathologi es, such as
hyperten sion and heart failure. The resultant apparent deteriora- 
tion of endothelium -dependent vasodilatation is termed ‘endothe- 
lial dysfunction ’. Endotheli al dysfunct ion presents decrease d
bioavaila bility of nitric oxide, a potent EDRF, in patients with 
essential hyperten sion, which may also be a key determinan t of
the premature developmen t of atherosclerosis and thrombosis 
[2,3]. Thus, therapeutic strategie s directed at improving endothe- 
lial dysfunction may result in decrease d morbidit y and mortality 
in hypertensive patients.
A growing body of evidence suggests that oxidative stress in the 
vasculatur e plays a pivotal role in endothelial dysfunction , and that 
the physical and chemical stresses induced by high pressure lead 
to augmented oxidative stress [4]. Vascular tone is largely depen- 
dent on the Ca2+ inﬂux across the plasma membrane through volt- 
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cle cells. Subtypes of VDCC, namely, the L-, N-, T- and P/Q-type 
channels are present in the vasculature, and blockers of L-type 
VDCCs are widely used in the treatment of hyperten sion [5,6].
Thus, lowering of the blood pressure (BP) by the blockade of L-type 
VDCCs is expected to reduce oxidative stress in the vasculature.
However, blockade of L-type VDCCs also results in activation of
the sympathetic tone because of its rapid vasodilator y effect 
[6,7]. Developmen t of new-generatio n L-type VDCC blockers to re- 
duce the undesired reﬂex sympathetic activation has been at- 
tempted, however , to date, success has not been achieved in
avoiding such sympathetic reﬂex activation by L-type VDCC block- 
ers [7,8]. In contrast, cilnidipine, a dihydropyridin e (DHP) deriva- 
tive that inhibits both N-type and L-type VDCCs [9,10], has been 
shown to be more effective than blockers of L-type VDCCs alone 
in patients with essential hypertension [11,12]. As N-type VDCCs 
are predominantl y distribut ed in the sympathetic nervous system 
and regulate the noradrenaline release from the sympathetic nerve 
endings [13,14], suppressi on of hemodynamic and autonomic re- 
ﬂexes by blockade of N-type VDCCs may underlie the potent anti- 
hypertensive effect of cilnidipine [11,15]. However, it is unclear 
whether cilinidipine suppresses oxidative stress-related endothe- 
lial dysfunct ion by inhibiting sympathetic tone. In addition, it has 
been reported recently that N-type VDCCs are also expressed in
the vasculature and that their gene expression levels are increased 
in hypertensive rats [16].
Activation of the renin-angio tensin system (RAS) is one of the 
major pathophysiologi cal mechanisms underlying the develop- 
ment of essential hypertension [17]. Stimulation of the angioten sin 
(Ang) II, type1 receptor (AT1R) induced by Ang II causes hyperten- 
sion by enhancing oxidative stress in the vasculature partly 
through mechanical stress-dep endent production of reactive oxy- 
gen species (ROS) [18–21]. Therefore, we investigated whether 
the N-type VDCCs participate in the endothelial dysfunction asso- 
ciated with the augmented oxidative stress induced by Ang II,
using mice lacking the a1B subunit (Cav 2.2) of N-type VDCCs.2. Materials and methods 
2.1. Materials 
Val5-Ang II was purchased from Peptide Institute. Paraform 
aldehyde and 10% formalin neutral buffer solution were purchased 
from Wako. Horseradi sh peroxidase-con jugated anti-rabb it IgG 
antibody was obtained from Santa Cruz Biotech. Heparin solution 
was from Mochida Pharmaceut ical Co. Ltd. Mayer’s Hematoxylin 
and eosin were from Muto Chemical Co. Ltd. Alexa Fluor 488 
anti-rat IgG, Alexa Fluor 546 anti-mouse IgG and dihydroethidium 
(DHE) were from Molecular Probes. Amlodipine was from Sigma.
Mouse anti-4-hydroxy- 2-nonenal (4-HNE) and anti-8-hyd roxy-2 0-
deoxyguanos ine (8-OH-dG) antibodie s were from the Japan Insti- 
tute for the Control of Aging (JaICA). Anti-CD68 antibody was from 
AbD Serotec, and anti-Ca v 2.2 antibody was from Alomone . Cilnid- 
ipine was synthesized in Ajinomoto Pharmaceutica l Co. Ltd.2.2. Animals and drug treatment 
The Cav 2.2-deﬁcient mice were developed by Dr. Yasuo Mori 
[14,22]. Their wild-type littermates (WT) served as the controls 
for all the studies. A mini osmotic pump (Alzet) ﬁlled with cilnid- 
ipine (30 mg/kg/day), amlodipine (10 mg/kg/day), or 100% poly- 
ethylene glycol (vehicle) was implanted intraperitonea lly into 8-
week-old mice, and after 3 days, another mini osmotic pump ﬁlled
with Val 5-Ang II (1 mg/kg/day) was implanted for continuous 
administrat ion of Ang II for 4 weeks. Increase in BP induced byAng II was conﬁrmed using the tail-cuff measurement method 
(Softron, BP-98A). Genotyping of the Cav 2.2-deﬁcient mice was 
performed using the polymera se chain reaction [14]. All animals 
were maintain ed in a conventional air-condi tioned room with a
time-con trolled lighting system. The handling and sacriﬁcing of
the animals were carried out in accordance with nationally pre- 
scribed guidelines , and ethical approval for the studies was ob- 
tained from the Animal Care and Use Committee of Kyushu 
Universit y.2.3. Isometric force measurements of mouse aortic rings 
Mice were sacriﬁced with sodium pentobarbital (50 mg/kg,
i.p.); the descending thoracic aorta was carefully isolated with 
any adherent connective tissue dissected out, and cut into 2-
mm-long rings [23]. Each ring was mounted between a pair of tri- 
angular stainless steel hooks, one of which was stationary and the 
other connected to a strain-gaug e transducer (UL10GR, Minebea ),
to record the isometric tension (MC6625, Graphtec, Tokyo, Japan).
The rings, placed in 20 ml organ baths containing Krebs Henseleit 
(KH) solution maintained at 37 C and aerated continuously with 
95% O2 and 5% CO2, were stretched to a resting tension of 1.5 g
and allowed to equilibrate for at least 30 min, with occasional 
changes of the KH solution. After equilibrati on, the rings were set 
at 1.5 g tension and incubated for 10 min. The endotheli al function 
was determined by examining the degree of relaxation in response 
to acetylcholine (ACh) of the aortic rings precontracted by KCl 
(60 mM).2.4. Analysis of the oxidative stress level and degree of macrophage 
inﬁltration in mouse aorta 
The aortic vessels were embedded in OCT compound (Leica) and 
frozen sections were prepared using a microtome (Cryostat; Leica,
CM1100). The OCT-embed ded sections (5 lm in thickness) were 
stained with anti-4-H NE (1/500), anti-8-OH-d G (1/500), and anti- 
CD68 (1/200) antibodies. The 4-HNE adducts and 8-OH-dG were 
visualized with Alexa Fluor 546 anti-mouse IgG antibody (1/
1,000, Molecular Probes). Digital photograp hs were taken at 60
magniﬁcation using confocal microscopy (FV10i, Olympus), and 5
regions were selected at random for each specimen of the vessel.
The average intensity was analyzed using the MetaMor ph Software 
(Molecular Devices).2.5. Measurem ent of ROS productio n and the intracellular Ca2+
concentrati on
Measurem ent of the intracellular Ca2+ concentratio n ([Ca2+]i)
was performed using fura-2 [24]. Production of ROS in bovine aor- 
tic endothelial cells (BAECs) was measure d using DHE [25]. Cells 
plated on 35-mm glass-based dishes were loaded with DHE 
(10 lM) at 37 C for 10 min prior to ATP treatment. The DHE ﬂuo-
rescence was observed using confocal microscopy at an emission 
waveleng th of 560 nm and excitation waveleng th of 543 nm.2.6. Statistica l analysis 
The results are shown as means ± SEM. All experiments were 
repeated at least three times. Statistical comparisons were per- 
formed using two-taile d Student’s t-test or one-way analysis of
variance followed by the Student–Newman-Keuls procedure, with 
the level of signiﬁcance set at P < 0.05.
Table 1
Hemodynamic parameter s and organ weights in the WT (Cav 2.2 (+/+)) and Cav 2.2- 
deﬁcient (Cav 2.2 (/)) mice.
Vehicle Ang II Ang II + CIL Ang II + AML 
Cav 2.2 (+/+) (n = 6) (n = 4) (n = 5) (n = 4)
HR (bpm) 581 ± 15 531 ± 22 579 ± 53 740 ± 18*,#
SBP (mmHg) 105 ± 3 143 ± 7* 106 ± 3# 104 ± 6#
HW/BW (mg/g) 4.3 ± 0.0 5.2 ± 0.1 * 4.2 ± 0.1 # 5.3 ± 0.2 *
KW/BW (mg/g) 5.8 ± 0.1 7.4 ± 0.1 * 6.2 ± 0.3 # 7.2 ± 0.2 *
Cav 2.2 (/) (n = 4) (n = 4) (n = 4) (n = 4)
HR (bpm) 623 ± 41 609 ± 50 655 ± 27 669 ± 24
SBP (mmHg) 103 ± 2 137 ± 5* 110 ± 6# 95 ± 10#
HW/BW (mg/g) 3.8 ± 0.1 4.4 ± 0.1 * 4.0 ± 0.1 4.1 ± 0.2 
KW/BW (mg/g) 5.2 ± 0.1 6.4 ± 0.2 * 5.4 ± 0.2 5.7 ± 0.2 
Abbreviations: CIL, cilnidipine; AML, amlodipine; HR, heart rate; SBP, systolic blood 
pressure; HW, heart weight; BW, body weight; KW, kidney weight.
* P < 0.05 versus vehicle group.
# P < 0.05 versus Ang II group.
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3.1. Involvement of N-type VDCCs in oxidative stress-related 
endothelial dysfuncti on induced by Ang II
As shown in a previous report [22], the basal heart rate and BP
in Cav 2.2-deﬁcient mice were almost equivalent to those in WT
mice (Table 1). Chronic Ang II treatment produced equivalent in- 
creases of BP in both WT and Cav 2.2-deﬁcient mice, indicating that 
Ang II-induce d signaling was not affected by the deletion of N-type 
VDCCs. Following 4-weeks’ treatment with Ang II, the WT mice 
showed impairment of ACh-induce d endothelium -dependent vas- 
cular relaxation of the thoracic aorta (Fig. 1A). In contrast, this 
Ang II-induced endothelial dysfunction was signiﬁcantly attenu- 
ated in Cav 2.2-deﬁcient mice (Fig. 1A and B). Oxidative stress 
due to loss of reduction /oxidation (redox) homeostasi s has been 
implicated in the occurrence of Ang II-induce d endothelial dys- 
function [4,19]. Chronic treatment with Ang II was shown to in- 
crease the expression of oxidized nucleotide (8-OH-dG) and fatty 
acid (4-HNE) in WT mouse thoracic aorta, while accumulation of
these oxidative stress markers was signiﬁcantly reduced in Cav
2.2-deﬁcient mouse thoracic aorta (Fig. 1C–F). These results indi- 90
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cilnidipine
We next examine d whether inhibition of the L/N-type VDCCs by
cilnidipine, in comparis on to that of the L-type VDCCs by amlodip- 
ine (a DHP derivative), exerts a beneﬁcial effect against Ang II-in- 
duced endothelial dysfunction in mice [26]. Treatment with 
amlodipine completely suppressed Ang II-induced increase of BP,
but caused signiﬁcant reﬂex tachycardia (Table 1). Treatment with 
cilnidipine also completely suppressed the increase of BP induced 
by Ang II, but without producing reﬂex tachycardia . While both 
cilnidipine and amlodipine suppressed the Ang II-induced impair- A B
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part via inhibition of the N-type VDCCs.
3.3. Requirement of N-type VDCCs for agonist-induc ed ROS production 
in endothelial cells 
Although stimulation of the AT1R by Ang II has been reported 
to induce ROS production in the vasculature via NADPH oxidase 
activation, it also induces ROS production via a mechanical 
stress-medi ated mechanis m [20,21]. We further examined 
whether N-type VDCCs are expressed and contribute to Ang II-in- 
duced ROS production in the endothelial cells, using human vas- 
cular endotheli al cells (HUVECs). Western blotting using anti-Ca v
2.2 antibody showed that the N-type VDCCs were expresse d in
HUVECs, but not in rat vascular smooth muscle cells (Fig. 3A).
We also found membrane expression of N-type VDCCs in bovine 
aortic endothelial cells (BAECs), however , neither the HUVECs 
nor the BAECs were responsive to Ang II or noradrenaline 
(Fig. 3B), suggestin g the scarce expression of AT1Rs and adrener- A
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high voltage-activat ed Ca2+ channels that can be selectively 
blocked by x-conotoxin (xCTx)-GVIA, a 27 amino-ac id peptide 
isolated from the venom of the ﬁsh-hunting cone snail, Conus
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elevation of the [Ca 2+]i were suppressed by xCTx-GVIA. We also 
found that treatment of BAECs with KCl (10 mM) induced moder- 
ate increase of the DHE ﬂuorescence intensity , which was sup- 
pressed by xCTx (data not shown). These results strongly 
suggest that N-type VDCCs contribute to ROS production associ- 
ated with a sustained increase in [Ca 2+]i in vascular endothelial 
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The involvement of N-type VDCCs in oxidative stress has been 
implicated previously in the kidney [29,30]. Cilnidipine has a po- 
tent renoprotective effect that is mediated by the blockade of N-
type VDCCs, including suppression of the RAS, renal ﬁbrosis and 
inﬂammation [29,31]. In fact, N-type VDCCs expressed in the nerve 
terminals have been revealed to mediate neurotransm itter release,
leading to constriction of afferent and efferent arterioles , and in- 
crease of the glomerular capillary pressure [32]. Slight reduction 
of heart rate by Ang II treatment was observed in WT mice, which 
was diminished in Cav 2.2-deﬁcient mice (Table 1). Chronic Ang II
infusion has been reported to decrease renal noradrenaline over- 
ﬂow in conscious dogs [33]. Thus, our data support the renoprotec- 
tive effect by inhibition of N-type VDCCs against the adverse 
effects of high BP. As Ang II-induced increase in BP remained unal- 
tered by inhibition of N-type VDCCs, N-type VDCCs may not partic- 
ipate in the Ang II-induced BP elevation.
We also demonstrated that the N-type VDCCs in endothelial 
cells contribute to the extracellular nucleotide (ATP)-induced
ROS production as well as sustained increase of the [Ca 2+]i in aor- 
tic endothelial cell lines. Stimulation of purinergi c P2X receptors 
is known to induce membran e depolarizati on via cation inﬂux,
leading to sustained Ca2+ inﬂux through the VDCCs [34]. Our pre- 
vious reports have shown that sustained increase in [Ca 2+]i is re- 
quired for agonist-induce d ROS production in cardiac cells [25].
As xCTx-GVIA partially suppressed ATP-induced ROS production 
(Fig. 3), N-type VDCCs may be one of the key players in ago- 
nist-induced ROS production in endothelial cells. We suggest for 
the ﬁrst time that N-type VDCCs in endotheli al cells, but not in
nerve terminals, directly contribute to ROS production, and that 
this participates in oxidative stress-related endotheli al dysfunc- 
tion in hypertensive mice. DHP derivatives work as lipophilic 
chain-break ing antioxidants [35], and potent antioxidant activity 
of cilnidipine has been reported [30]. The cilnidipine versus amlo-
dipine randomized trial for evaluation in renal disease (CARTER)
suggests that cilnidipine is superior to amlodipine for preventin g
the progression of proteinuria in hypertensive patients under 
treatment with a RAS inhibitor [26]. The same group has also re- 
ported that cilnidipine showed a signiﬁcantly higher antioxidant 
activity than amlodipine against ionomycin-s timulated superox- 
ide production in cultured human mesangial cells [30]. Another 
report has shown that cilnidipine suppresses cardiac remodeli ng
and diastolic dysfunction through inhibiting NADPH oxidase 
activity in Dahl salt-sensitive rats [36]. We did not investigate 
the mechanism underlying the N-type VDCC-mediate d ROS pro- 
duction, but these reports support the idea that Ca2+ inﬂux
through N-type VDCCs contribute to NADPH oxidase-mediated 
ROS production in endotheli al cells.
In conclusion, we demonstrat ed that the N-type VDCCs ex- 
pressed in endotheli al cells contribute to agonist-induce d ROS pro- 
duction and oxidative stress-related endothelial dysfunction in
Ang II-treated hypertensive mice. Our ﬁndings provide a novel in- 
sight into the mechanism underlying the progression of cardiovas- 
cular diseases caused by hyperten sion, and is thereby expected to
pave the way for the developmen t of a new therapeutic strategy to
decrease the morbidit y and mortality of hyperten sive patients.Acknowled gments 
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